

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED
石藥集團有限公司
(Incorporated in Hong Kong with limited liability)
(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

**“TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS”
OBTAINS DRUG REGISTRATION APPROVAL**

The board of directors (the “**Board**”) of the CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Tofacitinib Citrate Extended-Release Tablets (11mg)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

Tofacitinib is the first oral administrated small-molecule inhibitor of Janus kinase (JAK) which blocks the intracellular signaling associated with inflammation in moderately to severely active rheumatoid arthritis. The Product is indicated for the treatment of rheumatoid arthritis (RA). It adopts the principle of osmotic-controlled release mechanism, so that the drug can be released continuously and slowly to ensure the blood drug concentration is stable and unaffected by food. Further, the once-daily oral dosing facilitates the patients’ disease management. The Group has obtained the drug registration approval for Tofacitinib Citrate Tablets (5mg) in June 2021.

The approval of the Product will further enrich the Group’s product portfolio for autoimmune diseases.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 24 October 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.

* For identification purpose only